Capivasertib Extends Progression-Free Survival in Hormone Receptor-Positive Breast Cancer
The new AKT inhibitor doubled progression-free survival when added to treatment with Faslodex.
Thanks to Lifesaving Cancer Research18,000,000cancer survivors in the United States are living with, through, and beyond their disease.
Your donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now